Equities

CASI Pharmaceuticals Inc

CASI:NAQ

CASI Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)6.76
  • Today's Change-0.13 / -1.89%
  • Shares traded4.61k
  • 1 Year change+218.87%
  • Beta0.6464
Data delayed at least 15 minutes, as of Sep 18 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects CASI Pharmaceuticals Inc share price to fall to 6.00 in the next year from the last price of 6.76.
High-11.2%6.00
Med-11.2%6.00
Low-11.2%6.00

Earnings history & estimates in USD

On Aug 16, 2024, CASI Pharmaceuticals Inc reported 2nd quarter 2024 losses of -0.55 per share. This result exceeded the -0.63 consensus loss of the one analyst covering the company and exceeded last year's 2nd quarter results by 26.67%.
The next earnings announcement is expected on Nov 14, 2024.
Average growth rate-2.62%
CASI Pharmaceuticals Inc reported annual 2023 losses of -2.02 per share on Mar 28, 2024.
Average growth rate+14.97%
More ▼

Revenue history & estimates in USD

CASI Pharmaceuticals, Inc. had 2nd quarter 2024 revenues of 3.98m. This missed the 4.43m estimate of the one analyst following the company. This was 52.33% below the prior year's 2nd quarter results.
Average growth rate-16.48%
CASI Pharmaceuticals, Inc. had revenues for the full year 2023 of 33.88m. This was 21.41% below the prior year's results.
Average growth rate+96.81%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.